Sun Pharmaceutical Industries Ltd (SUNPHARMA) — Announcement | 22 September 2026

Sun Pharmaceutical Industries Limited presented its investor outlook for FY26, highlighting a diversified revenue base of Rs 582 Bn with 29% from US formulations, 33% from India, 19% from emerging markets, and 15% from rest of world. The presentation emphasized strong profitability with EBITDA margin reaching 30.3% in FY26, adjusted net profit margin of 21.2%, and ROCE of 30.3%. The company showcased its position as India's largest pharma firm with 8.5% market share, while detailing growth in innovative medicines contributing 22% of sales and a robust pipeline of 29 products. Global manufacturing spans 40 facilities with regulatory approvals across major markets.